A Phase 1-2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-Tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous

syn56417025

Created By NF Service nf-osi-service

studyName: A Phase 1-2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-Tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous
dataStatus: Data Pending
initiative: Partnership
studyLeads: Jaishri Blakeley Lu Le, Pierre Wolkenstein
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
institutions: Johns Hopkins University
fundingAgency: NTAP
manifestation: Plexiform Neurofibroma
studyFileviewId: syn56417144
syn56417106
syn56417111
syn56417144
syn56417116

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

A Phase 1-2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-Tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous page is loading…

A Phase 1-2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-Tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous

syn56417025

Drop files to upload

A Phase 1-2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-Tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous page is loading…